| Entry |
|
|---|
| Name |
Doxofylline (USAN/INN);
Maxivent (TN) |
|---|
| Formula |
C11H14N4O4
|
|---|
| Exact mass |
266.1015
|
|---|
| Mol weight |
266.2533
|
|---|
| Structure |
|
|---|
| Class |
Respiratory system agent
DG01616 Xanthine derivative
DG01609 Xanthine-type bronchodilator
|
|---|
| Remark |
|
|---|
| Efficacy |
Bronchodilator, Phosphodiesterase inhibitor |
|---|
| Comment |
Xanthine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03DA Xanthines
R03DA11 Doxofylline
D03898 Doxofylline (USAN/INN)
Drug groups [BR:br08330]
Respiratory system agent
DG01616 Xanthine derivative
DG01609 Xanthine-type bronchodilator
D03898 Doxofylline
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adenosine
ADORA2A
D03898 Doxofylline (USAN/INN)
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE2A
D03898 Doxofylline (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 19
1 N4y N 22.0098 -16.1293
2 C8y C 22.0098 -17.5262
3 N4y N 20.8224 -18.2246
4 C8y C 19.5653 -17.5262
5 C8y C 19.5653 -16.1293
6 C8y C 20.8224 -15.4309
7 N5x N 18.2383 -17.9453
8 C8x C 17.4700 -16.8278
9 N4y N 18.2383 -15.7103
10 O5x O 20.8224 -14.0341
11 O5x O 23.1971 -18.2246
12 C1b C 17.7839 -14.3894
13 C1y C 16.3784 -14.1158
14 O2x O 15.7797 -12.8300
15 C1x C 14.3717 -13.0021
16 C1x C 14.1003 -14.3943
17 O2x O 15.3405 -15.0826
18 C1a C 20.7693 -19.6120
19 C1a C 23.2224 -15.4357
BOND 21
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 5 9 1
11 6 10 2
12 2 11 2
13 9 12 1
14 12 13 1
15 13 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 13 17 1
20 3 18 1
21 1 19 1
|
|---|
